Eosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report
J Korean Med Sci. 2023 Dec 11;38(48):e382. doi: 10.3346/jkms.2023.38.e382.ABSTRACTThe current emergence of the coronavirus disease 2019 (COVID-19) pandemic and the possible side effects of COVID-19 mRNA vaccination remain worrisome. Few cases of vaccination-related side effects, such as vasculitis, have been reported. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a type of vasculitis characterized by the histological richness of eosinophils, asthma, polyneuropathy, sinusitis, and skin or lung involvement. Here, we report the first case of new onset EGPA following COVID-19 vaccination in Korea. A 71-year old woman developed a skin rash and presented with progressive weakness of the upper and lower extremities after the BNT162b2 vaccination (Pfizer-BioNTech). She was diagnosed with EGPA and her symptoms improved after systemic steroid and immunosuppressant therapy. Although it is very rare, clinicians should be aware that EGPA may occur after COVID-19 vaccination.PMID:38084026 | PMC:PMC10713438 | DOI:10.3346/jkms.2023.38.e382
Source: Journal of Korean Medical Science - Category: Biomedical Science Authors: Yu-Kyoung Hwang Hui-Hwan Kwak Jeong-Eun Yun Sae-Hoon Kim Yoon-Seok Chang Source Type: research
More News: Asthma | Biomedical Science | Churg-Strauss Syndrome | Coronavirus | Covid Vaccine | COVID-19 | Pandemics | Pfizer | Science | Sinusitis | Skin | Vaccines | Vasculitis